Our Paris Life Sciences team advised Bpifrance, and Andera Partners on their investment in the €27 million Series B financing of EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology.
The round was co-led by Andera Partners and Bpifrance, as part of the InnoBio investment strategy.
The financing will support the ongoing clinical study and further development of the platform.
The Goodwin team was led by Anne-Charlotte Rivière and included Johann Gandilhon and Charlotte Muller on corporate aspects and Marie Fillon, Louis de Chezelles and Albana Taipi on IP aspects.